¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69

Rockville, MD (Jan. 16, 2025) – In response to the Drug Enforcement Administration and Health and Human Services’ final rule, , Brian Hurley, MD, MBA, FAPA, DF¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69, president of the ¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69 (¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69), issued the following statement:  

“¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69 commends this final rule on the expansion of buprenorphine treatment for opioid use disorder (OUD) through audio-video or audio-only telemedicine encounters when the prescriber has not conducted an in-person medical evaluation of the patient prior to issuing a prescription.  

The final rule contains notable improvements from the original 2023 notice of proposed rulemaking (NPRM), such as significantly expanding the originally proposed initial 30-day prescription limitation to six months, removing the requirement for an in-person medical evaluation to issue additional prescriptions, introducing reasonable safeguards to protect against diversion, including a requirement for the remote prescriber to review the prescription drug monitoring program data of the patient’s state, and avoiding burdensome recordkeeping requirements initially proposed in the original NPRM.  

Once effective, this final rule will permanently preserve some of the critical, lifesaving telemedicine initiation flexibilities for buprenorphine treatment for OUD. These flexibilities, originally established under the first Trump administration, would remain in place beyond the . 

Additionally, the extension of a 30-day limit to six months allows the addiction medicine community to further study the impacts of this policy and adapt best practices to ensure patients with OUD have uninterrupted access to this lifesaving medication.  

¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69 appreciates this thoughtful final rule and looks forward to participating in ongoing discussions about the proposed rulemaking on special registrations for telemedicine and potential legislative action.” 

# # # 

About the ¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69    

The ¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69 (¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69), founded in 1954, is a professional medical society representing over 7,000 physicians, clinicians, and associated professionals in the field of addiction medicine. ¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69 is dedicated to increasing access and improving the quality of addiction treatment, educating physicians and the public, supporting research and prevention and promoting the appropriate role of physicians in the care of patients with addiction. For more information, visit www.¹ú²ú³ÉÈ˾«Æ·°×½¬¾Ã¾Ã69.org.